[177Lu]Lu-ABY-027

N/A

Report date: 2025/11/21 17:16:39

Base Information

Drug Name[177Lu]Lu-ABY-027
Drug Alias Name[177Lu]Lu-ABY-027177-Lu-ABY-027
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 binders
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUppsala UniversityAffibody Ab
China Registration ClassN/A

Develop Information

Active CompaniesAffibody AbUppsala University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A